News

ASCO 2015: Dr. William J. Gradishar gives his top picks in breast cancer research


 

References

Dr. William J. Gradishar picks the upcoming ASCO presentations he anticipates to be the most interesting in breast cancer research.

Dr. William Gradishar

Dr. William J. Gradishar

LBA500 Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.

501 Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).

LBA502 l PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.

503 Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.

504 Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.

507 Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.

508 Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase III, randomized, placebo-controlled trial (ExteNET).

1003 Results from a phase II study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

1004 Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.

520 Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).

521 DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial.

1015 A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).

1018 Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago.

Recommended Reading

Omega-3 fatty acids similar to placebo for aromatase inhibitor–induced musculoskeletal pain
MDedge Hematology and Oncology
ASA: Radiation lowers local recurrence risk for DCIS patients with close or positive margins
MDedge Hematology and Oncology
Cardiac monitoring falls short in elderly breast cancer patients given trastuzumab
MDedge Hematology and Oncology
Low-risk luminal A breast cancers may not require radiation Tx
MDedge Hematology and Oncology
Similar 5-year outcomes from accelerated partial-breast irradiation, whole-breast irradiation
MDedge Hematology and Oncology
Neoadjuvant chemotherapy for triple negative breast cancer improves conservation
MDedge Hematology and Oncology
Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US oncology survey
MDedge Hematology and Oncology
Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result
MDedge Hematology and Oncology
A quarter of women with dense breasts at high interval cancer risk
MDedge Hematology and Oncology
ACOG spells out risk assessment for hereditary cancer syndromes
MDedge Hematology and Oncology